Paltusotine (SK-5307)
Acromegaly and Pituitary Gigantism
Phase 2/3Active - Orphan Drug Designated in Japan
Key Facts
Indication
Acromegaly and Pituitary Gigantism
Phase
Phase 2/3
Status
Active - Orphan Drug Designated in Japan
Company
About Sanwa Kagaku Kenkyusho
Japanese pharmaceutical company developing novel treatments for metabolic and orphan diseases, with a lead candidate for acromegaly.
View full company profile